Suggested remit: To appraise the clinical and cost effectiveness of nivolumab in combination with cabozantinib within its marketing authorisation for untreated advanced or metastatic renal cell carcinoma.
Following consultation with the company, we will be suspending this topic and cancelling the scheduled committee meeting (7 July 2021) while discussions continue. We will provide an update when more information is available.
 
Status Suspended
Process STA 2018
ID number 1625

Project Team

Project lead Shonagh D'Sylva

Email enquiries

Consultees

Companies sponsors Bristol-Myers Squibb (nivolumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Kidney Cancer UK
  Kidney Care UK
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Novartis (pazopanib) (not participating)
  Pfizer (sunitinib)
  Eusa Pharma UK (tivozanib) (not participating)
  Ipsen (cabozantinib)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
21 April 2021 Suspended. Following consultation with the company, we will be suspending this topic and cancelling the scheduled committee meeting (7 July 2021) while discussions continue. We will provide an update when more information is available.
15 March 2021 Please note that due to operational reasons the committee meeting has been delayed. We are aware that the appraisal is currently undergoing technical engagement. Given the delay we are proposing to extend the deadline for responses to technical engagement until 26 March 2021. We will provide an update when the appraisal has been rescheduled.
28 August 2020 Invitation to participate
23 April 2020 - 22 May 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
17 October 2018 In progress. DHSC referral received.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance